Patent Grant
10172849
This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.
Buprenorphine (also known as (2S)-2-[(−)-(5R,6R,7R,14S)-9α-cyclo-propyl-methyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-di-methylbutan-2-ol and marketed under the trade names SUBUTEX™ and SUBOXONE™ for relief of opioid addiction.
The chemical structure of buprenorphine is shown in formula (1).
Buprenorphine is most often used to treat symptoms arising from opioid addiction and for the long term relief of pain. Currently, the commercial opioid addiction products are SUBUTEX™ and SUBOXONE™ marketed by RB Pharma Inc. These products are in a tablet formulation and are intended to deliver therapeutic levels of buprenorphine for short periods of time of up to several hours and are typically taken either buccally or sublingually. However, the patient is required to supplement this dose at regular intervals, and there are often issues with diversion in patients with an opioid dependence problem. There is a need therefore for a longer term, non-divertible method of administering buprenorphine which delivers a constant and effective dose of the active to the patient over a period of up to 30 days, and which does not result in an unwanted accumulation of residual active in the patient's metabolism.
Various sustained release methods are employed in the pharmaceutical industry, for example, systems such as solid, biodegradable rods, or nondegradable reservoirs. These, however, typically require surgical implantation and furthermore, for the nondegradable delivery systems, a second surgical procedure is required to remove the empty reservoir.
There is a continuing need to develop products providing increased bioavailability of buprenorphine. In particular, there is a need to develop sustained release formulations of buprenorphine that do not suffer from low bioavailability, poor release kinetics, injection site toxicity, relatively large volume injections, and inconveniently short duration of release.
The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 7 days to about 1 month. The buprenorphine sustained release delivery system includes a flowable composition for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The buprenorphine sustained release delivery system provides at least 7 days and up to 30 days release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.
Surprisingly, it has been found that such a sustained release delivery system is achieved by a composition comprising a suspension of buprenorphine in water, wherein the buprenorphine is in particulate form.
Accordingly, there is provided according to the first embodiment of the present invention, a composition comprising a suspension of 5-20 wt % of buprenorphine in water; and, a polyethylene glycol (PEG) polymer, wherein the buprenorphine is in particulate form with an average particle size of less than 200μ; and, the composition does not comprise a polylactide or polyglycolide polymer or mixture thereof.
Preferably, the average particle size of the buprenorphine in the composition as hereinbefore described is less than 150μ, preferably less than 120μ, preferably less than 100μ, preferably less than 80μ, preferably less than 60μ, preferably less than 50μ, preferably less than 40μ.
Especially preferably, the average particle size of the buprenorphine in the composition as hereinbefore described is less than 20μ, more especially preferably less than 10μ.
In one preferred embodiment, the composition as hereinbefore described comprises buprenorphine present as the free base (unprotonated) form.
In another preferred embodiment, the composition as hereinbefore described comprises buprenorphine present as a protonated salt form.
In a further preferred embodiment, the composition as hereinbefore described further comprises a water soluble polymer selected from the group consisting of polyethylene glycols (PEG), carboxymethylcelluloses (CMC), polyvinylpyrrolidones (PVP), polyvinylalcohols (PVA) and dextrans.
In a yet further embodiment, there is provided a composition as hereinbefore described wherein the water soluble polymer is a PEG, preferably wherein the PEG has a MW of between 1000 to 10,000.
In a yet further embodiment, there is provided a composition according to any preceding claim which further comprises a nonionic surfactant selected from the group consisting of Tween 20, Tween 80, poloxamers and phospholipids, preferably wherein the surfactant is one or both of Tween 20 or Tween 80.
In a yet further embodiment, there is provided a composition according to any preceding claim further comprising pharmaceutically acceptable salts or sugars to adjust the tonicity of the composition, and/or preservatives, preferably selected from the group consisting of methylparaben, propylparaben and benzylalcohol.
In a second embodiment of the present invention, there is provided a method of treating a patient for opioid dependence or pain relief comprising administering parenterally and extravascularly a composition substantially as hereinbefore described according to the first embodiment of the present invention.
Preferably, the method according to the second embodiment provides treatment for opioid dependence or pain relief over a period of at least 7 days.
Preferably, the method according to the second embodiment provides treatment for opioid dependence or pain relief over a period of no more than 30 days.
In a particular preference, the method of treating a patient according to the second embodiment provides treatment for opioid dependence or pain relief over a period of at least 7 days and no more than 28 days.
Further preferably, the method of treatment according to the second embodiment provides treatment for opioid dependence or pain relief over a period of at least 10 days and no more than 17 days.
In a further preference of the second embodiment of the invention, there is provided a method of treating a patient comprising a dosage regime of an initial dose plus follow up dosages at a regular time interval of between 7 and 30 days.
In a yet further preference of the second embodiment of the invention, there is provided a method substantially as hereinbefore described which delivers a therapeutically effective dosage of the buprenorphine, metabolite, or prodrug thereof from about 0.1 to about 10 milligrams (mg) or about 1 to about 8 milligrams (mg) per day.
In a yet further preference of the second embodiment of the invention, there is provided a method substantially as hereinbefore described wherein the dosage achieves a therapeutically effective level of the buprenorphine, metabolite, or prodrug thereof, within about one day after administration of the composition; and wherein the therapeutically effective dosage of the buprenorphine, metabolite, or prodrug thereof is delivered for at least about 7 days after administration of the composition, or for at least about 30 days after administration of the composition.
In a third embodiment of the present invention, there is provided a method of forming a composition according to the first embodiment of the invention comprising the steps of: (a) mixing the water with any further optional component, (b) add the opioid agonist along with a grinding medium, and (c) grinding the suspension until the required particle size is achieved.
In a preferred method according to the third embodiment of the present invention, the method further comprises the process of terminally sterilizing the composition, which process comprises the steps of: (a) fill the composition in pharmaceutically acceptable vials or ampoules and properly seal the vials or ampoules, and (b) terminally sterilizing the vials or ampoules by autoclaving or irradiation (gamma or electron beam).
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
Studies in Rats
Experimental Procedures. All rat preclinical studies were conducted in Sprague-Dawley rats. Five rats per Test Article per time point were injected either intramuscularly or subcutaneously under full anesthesia in the dorsal thoracic (DT) region with approximately 200 mg of the Test Article, described above.
During the course of the study, the animals were observed for overt toxicity and any existing test site abnormalities, including redness, bleeding, swelling, discharge, bruising and Test Article extrusion at the injection site were observed and recorded. In addition, injection weights were recorded at administration and body weights were taken and recorded at administration and at termination. At selected time points, five rats per Test Article were anesthetized and bled (about 5 mL) via cardiac puncture. Blood was collected in labeled potassium ethylenediaminetetraacetic acid tubes. The blood was centrifuged for 10 min at 3000 rpm. The plasma fraction was transferred to labeled 5 mL plastic culture tubes and stored at −86° C. The rat plasma samples were analyzed for buprenorphine concentration using a procedure described below. After blood collection, the rat was sacrificed in a carbon dioxide chamber. The injection site was cut open and the drug residue and the surrounding tissues were carefully removed and placed in a scintillation vial. The vials were stored at −20° C. until analysis. The retrieved drug residue/tissue was analyzed for buprenorphine content using the implant analysis method described below.
Buprenorphine Analysis in Rat Plasma Samples
This procedure was based on that described by Li-Heng Pao et al., Journal of Chromatography B, 746(2000), 241-247.
The High Performance Liquid Chromatography had the following conditions: Mobile Phase: 80/20 acetonitrile/5 mM sodium acetate buffer (pH 3.75); flow rate: 1.2 mL/min; autosampler temperature: room temperature; column temperature: 25° C.; detection: fluorescence (excitation at 215 nm and emission at 355 nm); total run time: 14 min; injection volume: 50 μL; column: Phenomenex Luna Silica (2) 250×4.6 mm, 5 μm; column storage: 100% acetonitrile; approximate retention time for buprenorphine and the internal standard: 7.9 min and 8.7 min.
Implant Extraction/Analysis Procedure
To the vials containing the retrieved drug residue/tissue, exactly 10 mL of the formulation dissolution solution (90/5/5 acetonitrile/glacial acetic acid/water) was added. The vials were then shaken at about 200 rpm at room temperature on the orbital shaker for at least 2 hours. The vials were then centrifuged at 2500 rpm for 10 minutes. After centrifuge, the vials were carefully removed from the centrifuge. A portion of the supernatant from the vial was transferred into a HPLC vial and if necessary, the transferred solution in the vial was further diluted using the formulation dissolution solution to a suitable concentration for HPLC analysis.
The High Performance Liquid Chromatography had the following conditions: Mobile Phase A: 0.065% sodium octanesulfonic acid and 0.1% trifluoroacetic acid in water; Mobile Phase B: 90/10 acetonitrile/0.065% sodium octanesulfonic acid and 0.1% trifluoroacetic acid in water; flow rate: 1.0 ml/min; autosampler temperature: room temperature; column temperature: 30° C.; detection: 285 run (UV); total run time: 21 min; injection volume: 20 μL; column: Phenomenex Luna C18 250×4.6 mm, 5 μm; column storage: 70/30 acetonitrile/water; each sample run according to the following gradient program:
approximate retention time of buprenorphine: 15.4 minutes.
The standard solution preparation is as follows: standard stock solution was made by dissolving approximately 10 mg buprenorphine in 10 mL 1:1 formulation dissolution solution (90/5/5 acetonitrile/glacial acetic acid/water)/H2O. A series standards ranging from 40 ppm to 500 ppm was diluted with water from the standard stock solution.
Studies in Dogs
Experimental Procedures. All dog preclinical studies were conducted in male beagles with body weight in the range of 8-12 kg. Six dogs per group were injected subcutaneously in the dorsal thoracic region or intramuscularly in the hind legs at a buprenorphine equivalent dose of 60 mg per dog. Exact injection doses were obtained by weighing the injection syringe before and after each injection. After injection, the dogs were bled periodically via jugular vein into EDTA tubes. Plasma samples were then derived and stored in a −80° C. freezer until analysis. Dogs were weighed once daily on blood collection time points. The test sites were evaluated for any abnormalities including redness, bleeding, swelling, discharge, bruising, and TA extrusion on blood collection days. Dogs were also observed post-administration for signs of overt toxicity throughout the entire study period.
Buprenorphine Analysis in Dog Plasma Samples
Plasma samples from dog studies were analyzed for buprenorphine and norbuprenorphine levels using a LC-MS-MS method through a contract analytical service laboratory. The method was developed and validated by the contract service laboratory. It was a proprietary method that employed a liquid-liquid extraction step followed by LC-MS-MS analysis.
1. Preparation of Buprenorphine Free Base Aqueous Suspension
Exactly 3.0 g PEG3350, 0.2 g Tween 80, and 0.9 g sodium chloride were weighed in a 100-ml volumetric flask. Water was added to dissolve and made up to 100 ml. An aliquot of 17.6 g of this aqueous solution was transferred to a 60-ml glass jar, buprenorphine free base (2.4 g) was then weighed in the jar. The jar was further placed in about 20 half inch size Burundum grinding beads. The jar was closed with a lid and then placed on ajar mill to rotate at 60 rpm at room temperature for 24 hours. The buprenorphine suspension was then filled in 1-ml glass ampoules. The filled ampoules were sealed and autoclaved at 121° C. for 15 minutes. Mean buprenorphine free base particle size [d(0.5)] was measured to be 8.3μ by the Malvern Mastersizer 2000 particle size analyzer.
2. Subcutaneous Injection of Micronized Buprenorphine Free Base Aqueous Suspension in Rats.
Formulation: 10% buprenorphine free base suspension in 3% PEG3350 and 0.2% Tween 80 aqueous solution, micronized, subcutaneous injection of 0.2 ml formulation per rat (20 mg bup per rat) (particle size 3.7μ)
Results:
3. Intramuscular Injection of Micronized Buprenorphine Free Base Aqueous Suspension in Rats.
Formulation: 13.3% buprenorphine free base suspension in 3% PEG3350, 0.2% Tween 80, and 0.9% sodium chloride aqueous solution, micronized, intramuscular injection of 0.15 ml formulation per rat (20 mg bup per rat) (particle size 10.5μ).
Results:
4. Subcutaneous Injection of Micronized/Larger Particle Size Buprenorphine Free Base Aqueous Suspensions as Well as Buprenorphine Hydrochloride Suspension in Rats) (Particle Size Group I=4.7μ, Group II=40.3μ)
Formulation:
Group I: 10% buprenorphine free base suspension in 0.2% Tween 80 and 0.9% sodium chloride aqueous solution, micronized, subcutaneous injection of 0.20 ml formulation per rat (20 mg bup per rat)
Group II: 10% buprenorphine free base suspension in 0.2% Tween 80 and 0.9% sodium chloride aqueous solution, subcutaneous injection of 0.20 ml formulation per rat (20 mg bup per rat)
Group III: 10% buprenorphine hydrochloride suspension in 0.2% Tween 80 and 0.9% sodium chloride aqueous solution, micronized, subcutaneous injection of 0.20 ml formulation per rat (20 mg bup per rat)
Results:
5. Subcutaneous and Intramuscular Injections of Micronized Buprenorphine Free Base Aqueous Suspension in Dogs)
Formulation: 12% buprenorphine free base suspension in 3% PEG3350, 0.2% Tween 80, and 0.9% sodium chloride aqueous solution, micronized, subcutaneous and intramuscular injection of 0.5 ml formulation per dog (60 mg bup per dog) (particle size 8.3μ).
Results:
This application is a continuation of U.S. application Ser. No. 13/703,015 filed Feb. 5, 2013, issued as U.S. Pat. No. 9,295,645, which is a § 371 of PCT/GB2011/51058 filed Jun. 6, 2011, which claims priority to United Kingdom Application No. GB 1009546.1 filed Jun. 8, 2010.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3466362 | Klaui et al. | Sep 1969 | A |
| 4534974 | Kim | Aug 1985 | A |
| 4573995 | Chen et al. | Mar 1986 | A |
| 4599354 | Shulman | Jul 1986 | A |
| 4626539 | Aungst et al. | Dec 1986 | A |
| 4755389 | Jones et al. | Jul 1988 | A |
| 4784855 | Yamashita et al. | Nov 1988 | A |
| 4804663 | Kennis et al. | Feb 1989 | A |
| 4938763 | Dunn et al. | Jul 1990 | A |
| 5008110 | Benecke et al. | Apr 1991 | A |
| 5026556 | Drust et al. | Jun 1991 | A |
| 5069909 | Sharma et al. | Dec 1991 | A |
| 5096715 | Sinclair | Mar 1992 | A |
| 5173304 | Lohner et al. | Dec 1992 | A |
| 5324519 | Dunn et al. | Jun 1994 | A |
| 5346903 | Ackerman et al. | Sep 1994 | A |
| 5453425 | Francois et al. | Sep 1995 | A |
| 5486362 | Kitchell et al. | Jan 1996 | A |
| 5616587 | Francois et al. | Apr 1997 | A |
| 5648093 | Gole et al. | Jul 1997 | A |
| 5688801 | Mesens et al. | Nov 1997 | A |
| 5702716 | Dunn et al. | Dec 1997 | A |
| 5744153 | Yewey et al. | Apr 1998 | A |
| 5770231 | Mesens et al. | Jun 1998 | A |
| 5780044 | Yewey et al. | Jul 1998 | A |
| 5792477 | Rickey | Aug 1998 | A |
| 5948787 | Merrill | Sep 1999 | A |
| 5990194 | Dunn et al. | Nov 1999 | A |
| 6004969 | Hu | Dec 1999 | A |
| 6120789 | Dunn | Sep 2000 | A |
| 6224905 | Lawrence et al. | May 2001 | B1 |
| 6261583 | Dunn et al. | Jul 2001 | B1 |
| 6264987 | Wright et al. | Jul 2001 | B1 |
| 6284274 | Merrill et al. | Sep 2001 | B1 |
| 6294192 | Patel et al. | Sep 2001 | B1 |
| 6303137 | Dittgen et al. | Oct 2001 | B1 |
| 6355657 | Osborne | Mar 2002 | B1 |
| 6383471 | Chen et al. | May 2002 | B1 |
| 6395293 | Polson et al. | May 2002 | B2 |
| 6413536 | Gibson et al. | Jul 2002 | B1 |
| 6528080 | Dunn et al. | Mar 2003 | B2 |
| 6565874 | Dunn et al. | May 2003 | B1 |
| 6596316 | Lyons et al. | Jul 2003 | B2 |
| 6630155 | Chandrashekar et al. | Oct 2003 | B1 |
| 7041320 | Nuwayser | May 2006 | B1 |
| 7410635 | Blondino et al. | Aug 2008 | B2 |
| 7501113 | Blondino | Mar 2009 | B2 |
| 7691408 | Leroux et al. | Apr 2010 | B2 |
| 8114383 | Bartholomaus et al. | Feb 2012 | B2 |
| 8114429 | Michal et al. | Feb 2012 | B2 |
| 8133507 | Yum et al. | Mar 2012 | B2 |
| 8173148 | Dadey et al. | May 2012 | B2 |
| 8221778 | Siegel et al. | Jul 2012 | B2 |
| 8236755 | Thuresson et al. | Aug 2012 | B2 |
| 8257722 | Michal et al. | Sep 2012 | B2 |
| 8313763 | Margaron et al. | Nov 2012 | B2 |
| 8324343 | Moore et al. | Dec 2012 | B2 |
| 8329203 | Siegel et al. | Dec 2012 | B2 |
| 8333989 | Sukuru | Dec 2012 | B2 |
| 8377479 | Talton | Feb 2013 | B2 |
| 8415401 | Yum et al. | Apr 2013 | B2 |
| 8512749 | Sawhney et al. | Aug 2013 | B2 |
| 8563023 | Michal et al. | Oct 2013 | B2 |
| 8574552 | Stroppolo et al. | Nov 2013 | B2 |
| 8586103 | Li et al. | Nov 2013 | B2 |
| 8815944 | Leroux et al. | Aug 2014 | B2 |
| 8852638 | Luk et al. | Oct 2014 | B2 |
| 8877241 | Fischer et al. | Nov 2014 | B2 |
| 8916202 | Lebon et al. | Dec 2014 | B2 |
| 8921387 | Norton et al. | Dec 2014 | B2 |
| 8975270 | Norton et al. | Mar 2015 | B2 |
| 9017709 | Griguol et al. | Apr 2015 | B2 |
| 9044450 | Luk et al. | Jun 2015 | B2 |
| 9168216 | Gavin et al. | Oct 2015 | B2 |
| 9221831 | Kyle et al. | Dec 2015 | B2 |
| 9254268 | Krayz et al. | Feb 2016 | B2 |
| 9259872 | Hayes et al. | Feb 2016 | B2 |
| 9272044 | Norton et al. | Mar 2016 | B2 |
| 9295645 | Norton et al. | Mar 2016 | B2 |
| 9308162 | Norton | Apr 2016 | B2 |
| 9326979 | Kimura et al. | May 2016 | B2 |
| 9364518 | Nadkarni et al. | Jun 2016 | B2 |
| 9415034 | Oliver et al. | Aug 2016 | B2 |
| 9468599 | Ray, II et al. | Oct 2016 | B2 |
| 9498432 | Norton et al. | Nov 2016 | B2 |
| 9555226 | Zumbrunn et al. | Jan 2017 | B2 |
| 9597402 | Luk et al. | Mar 2017 | B2 |
| 20030004100 | Dasch et al. | Jan 2003 | A1 |
| 20030068375 | Wright et al. | Apr 2003 | A1 |
| 20030129219 | Hong et al. | Jul 2003 | A1 |
| 20030211157 | Simon | Nov 2003 | A1 |
| 20040018238 | Shukla | Jan 2004 | A1 |
| 20040033250 | Patel et al. | Feb 2004 | A1 |
| 20040101557 | Gibson et al. | May 2004 | A1 |
| 20040138237 | Shah | Jul 2004 | A1 |
| 20040151670 | Blondino et al. | Aug 2004 | A1 |
| 20050032781 | Ehrich | Feb 2005 | A1 |
| 20050048115 | Mangena et al. | Mar 2005 | A1 |
| 20050048123 | Su et al. | Mar 2005 | A1 |
| 20050053647 | Matusch et al. | Mar 2005 | A1 |
| 20050112067 | Kumar et al. | May 2005 | A1 |
| 20060002979 | Ashammakhi et al. | Jan 2006 | A1 |
| 20060003008 | Gibson et al. | Jan 2006 | A1 |
| 20060210604 | Dadey et al. | Sep 2006 | A1 |
| 20070077304 | Luk et al. | Apr 2007 | A1 |
| 20070117828 | Simmons et al. | May 2007 | A1 |
| 20070265190 | Thuresson et al. | Nov 2007 | A1 |
| 20080020011 | Finkelstein et al. | Jan 2008 | A1 |
| 20080020039 | Parikh et al. | Jan 2008 | A1 |
| 20080299168 | Dadey et al. | Dec 2008 | A1 |
| 20090048145 | Hellerbrand et al. | Feb 2009 | A1 |
| 20090061011 | Talton | Mar 2009 | A1 |
| 20090074708 | Oliver et al. | Mar 2009 | A1 |
| 20090092650 | Warren et al. | Apr 2009 | A1 |
| 20090202481 | Li et al. | Aug 2009 | A1 |
| 20090246265 | Stinchcomb et al. | Oct 2009 | A1 |
| 20100098735 | Jain et al. | Apr 2010 | A1 |
| 20100173940 | Leichs et al. | Jul 2010 | A1 |
| 20100266655 | Dadey | Oct 2010 | A1 |
| 20100292195 | Dadey et al. | Nov 2010 | A1 |
| 20100330150 | Venkatesh et al. | Dec 2010 | A1 |
| 20110229526 | Rosenberg et al. | Sep 2011 | A1 |
| 20110230816 | Copp-Howland | Sep 2011 | A1 |
| 20120058158 | Booles | Mar 2012 | A1 |
| 20120207843 | Lebon et al. | Aug 2012 | A1 |
| 20130023553 | Jude-Fishburn et al. | Jan 2013 | A1 |
| 20130129828 | Talton | May 2013 | A1 |
| 20130143909 | Chong et al. | Jun 2013 | A1 |
| 20130177603 | Gutierro Aduriz et al. | Jul 2013 | A1 |
| 20130202658 | Norton et al. | Aug 2013 | A1 |
| 20130210751 | Dong et al. | Aug 2013 | A1 |
| 20130231359 | Chong et al. | Sep 2013 | A1 |
| 20130331803 | Fleschhut et al. | Dec 2013 | A1 |
| 20140023692 | Du Toit et al. | Jan 2014 | A1 |
| 20140134261 | Singh et al. | May 2014 | A1 |
| 20140271869 | Richey et al. | Sep 2014 | A1 |
| 20140363487 | Hille et al. | Dec 2014 | A1 |
| 20150209555 | Ruane et al. | Jul 2015 | A1 |
| 20150231258 | Luk et al. | Aug 2015 | A1 |
| 20150359891 | Chen et al. | Dec 2015 | A1 |
| 20160303038 | Yadav et al. | Oct 2016 | A1 |
| 20170079974 | Zhou et al. | Mar 2017 | A1 |
| 20170079976 | Norton et al. | Mar 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 0 368 409 | May 1990 | EP |
| 0 368 409 | May 1990 | EP |
| 0 532 546 | Mar 1993 | EP |
| 0 532 546 | Mar 1993 | EP |
| 0 572 494 | Dec 1993 | EP |
| 0 572 494 | Dec 1993 | EP |
| 1 006 935 | Jun 2000 | EP |
| 1 006 935 | Jun 2000 | EP |
| 1 015 032 | Jul 2000 | EP |
| 1 644 002 | Apr 2006 | EP |
| 1 644 002 | Apr 2006 | EP |
| 1 830 900 | Sep 2007 | EP |
| 1 940 351 | Jul 2008 | EP |
| 1 940 351 | Jul 2008 | EP |
| 2 081 574 | Jul 2009 | EP |
| 2 361 609 | Aug 2011 | EP |
| 2 361 609 | Aug 2011 | EP |
| 2 445 487 | May 2012 | EP |
| 2 797 602 | Nov 2014 | EP |
| 784659 | Oct 1957 | GB |
| 806876 | Jan 1959 | GB |
| 873526 | Jul 1961 | GB |
| 887872 | Jan 1962 | GB |
| 1535DEL2004 | Aug 2006 | IN |
| WO-199119474 | Dec 1991 | WO |
| WO-9323019 | Nov 1993 | WO |
| WO-9527481 | Oct 1995 | WO |
| WO-9621427 | Jul 1996 | WO |
| WO-9639095 | Dec 1996 | WO |
| WO-9858685 | Dec 1998 | WO |
| WO-0006117 | Feb 2000 | WO |
| WO-00024374 | May 2000 | WO |
| WO-0115699 | Mar 2001 | WO |
| WO-0135929 | May 2001 | WO |
| WO-0135929 | May 2001 | WO |
| WO-0230393 | Apr 2002 | WO |
| WO-0230393 | Apr 2002 | WO |
| WO-02038185 | May 2002 | WO |
| WO-02038185 | May 2002 | WO |
| WO-2004037259 | May 2002 | WO |
| WO-2003041684 | May 2003 | WO |
| WO-2003041684 | May 2003 | WO |
| WO-2004043432 | May 2004 | WO |
| WO-2004043432 | May 2004 | WO |
| WO-2006041942 | Apr 2006 | WO |
| WO-2006041942 | Apr 2006 | WO |
| WO-2006053175 | May 2006 | WO |
| WO-2006053175 | May 2006 | WO |
| WO-2007041410 | Apr 2007 | WO |
| WO-2007041410 | Apr 2007 | WO |
| WO-2007061828 | May 2007 | WO |
| WO-2007061828 | May 2007 | WO |
| WO-2007103185 | Sep 2007 | WO |
| WO-2007103185 | Sep 2007 | WO |
| WO-2008045516 | Apr 2008 | WO |
| WO-2008100532 | Aug 2008 | WO |
| WO-2008153611 | Dec 2008 | WO |
| WO-2008153611 | Dec 2008 | WO |
| WO-2009091737 | Jul 2009 | WO |
| WO-2009091737 | Jul 2009 | WO |
| WO-2011154724 | Dec 2011 | WO |
| WO-2011154724 | Dec 2011 | WO |
| WO-2011154724 | Dec 2011 | WO |
| WO-2011154725 | Dec 2011 | WO |
| WO-2011154725 | Dec 2011 | WO |
| WO-2014016428 | Jan 2014 | WO |
| WO-2014081343 | May 2014 | WO |
| WO-2014081343 | May 2014 | WO |
| WO-2015136253 | Sep 2015 | WO |
| Entry |
|---|
| Aird, J. (Apr. 2003). Controlled Release—SMi Conference. Feb. 12-13, 2003, London,UK, IDrugs 6(4):334-336. |
| Astaneh, R. et al. (Jan. 2009). “Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior,” J Pharm Sci 98(1):134-145. |
| Baker, D.L. et al. (Oct. 2004). “Gonadotropin-releasing hormone agonist: a new approach to reversible contraception in female deer,” J Wildl Dis 40(4):713-724. |
| Bartsch, W. et al. (1976). “Acute Toxicity in Various Solvents in the Mouse and Rat,” Arzneim-Forsch, Drug Res 26:1581-1583. |
| Basu, S.K. et al. (Mar. 2004). “Protein crystals for the delivery of biopharmaceuticals,” Expert Opin Biol Ther 4(3):301-317. |
| Becci, P.J. et al. (1983). “Subchronic feeding study in beagle dogs of N-methylpyrrolidone,” J Appl Toxicol 3(2):83-86. |
| Berges, R. et al. (2005). “Eligard®: Pharmacokinetics, effect on Testosterone and PSA Levels and Tolerability,” European Urology Supplements 4:20-25. |
| Boongird, A. et al. (Jan. 2011). “Biocompatibility study of glycofurol in rat brains,” Exp Biol Med 236(1):77-83. |
| Bowersock, T.L. et al. (1999). “Vaccine delivery to animals,” Adv Drug Deliv Rev 38(2):167-194. |
| Bromberg, L.E. et al. (Jul. 31, 2000). “Sustained release of silver from periodontal wafers for treatment of periodontitis,” J Control Release 68(1):63-72. |
| Chandrashekar, B.L. et al. (Jul. 1999). “Sustained Release of Leuprolide Acetate from an In-situ Forming Biodegradable Polymeric Implant as the Delivery Vehicle,” Proceed Int'l Symp Control Rel Bioact Mater 26, 3 pages. |
| Chen, F.A. et al. (Jul. 2003). “Biodegradable polymer-mediated intratumoral delivery of cisplatin for treatment of human head and neck squamous cell carcinoma in a chimeric mouse model,” Head Neck 25(7):554-560. |
| Chu, F.M. et al. (Sep. 2002). “A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer,” Journal of Urology 168(3):1199-1203. |
| Contet C, Kieffer BL, Befort K. Mu opioid receptor: a gateway to drug addiction. Curr Opin Neurobiol 14:370-378, 2004. |
| Coonts, B.A. et al. (Oct. 1993). “Plasma Concentrations of Naltrexone Base Following Subcutaneous and Intramuscluar Injections of Atrigel™ Formulations in Dogs,” Pharmaceutical Research: Official Journal of the American Association of Pharmaceutical Scientists PHREEB 10(10):PDD 7071, 2 pages. |
| Cox, M.G. et al. (Aug. 2005). “Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?” Expert Rev Anticancer Ther 5(4):605-611. |
| Crawford, E.D. et al. (Feb. 2006). “A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer,” Journal of Urology 175(2):533-536. |
| Dadey, E.J. (2008). The Atrigel Drug Delivery System. In: Rathbone et al Eds, Modified-Release Drug Delivery Technology, 2nd Ed., New York, pp. 183-190. |
| Dernell, W.S. et al. (1998). “Apparent interaction of dimethyl sulfoxide with cisplatin released from polymer delivery devices injected subcutaneously in dogs,” J Drug Target 5(5):391-396. |
| Domb, A.J. et al. (1989). “Solid-State and Solution Stability of Poly(anhydrides) and Poly(esters,” Macromolecules 22(5):2117-2122. |
| Dunn, R.S., (2003). “The Atrigel Drug Delivery System,” Modified-Release Drug Delivery Technology, Edited by Rathbone, Hadgraft, Roberts, Marcel Dekker, Inc., Chapter 54, pp. 647-655. |
| Dunn, R.L. et al (1996). “Sustained Release of Cisplatin in Dogs from an Injectable Implant Delivery System,” Journal of Bioactive and Compatible Polymers, 11:286-300. |
| Duysen, E.G. et al (1992). “Bioactivity of Polypeptide Growth Factors Released from the ATRIGEL Drug Delivery System,” PHREEB, 9(10):S73, Abstract No. 2028. |
| Duysen, E.G. et al (1993). “Release of Bioactive Growth Factors from the ATRIGEL Delivery System in Tibial Defect and Dermal Wound Models,” PHREEB, 10(10):583, Abstract No. 2043. |
| Duysen, E.G. et al (1994). “An Injectable, Biodegradable Delivery System for Antineoplastic Agents,” PHREEB, 11(10):S88, Abstract No. 2071. |
| Eliaz, R.E. et al. (Dec. 2000). “Delivery of soluble tumor necrosis factor receptor from in-situ forming PLGA implants: in-vivo,” Pharm Research 17(12):1546-1550. |
| Erickson, N.M. et al. (2001). “An in Vitro Degradation Study Comparing Poly (DL-Lactide-Co-Glycolide) with Acid End Groups and Ester End Groups,” 20th Southern Biomedical Engineering Conference, 1 page. |
| Evans, H.C., et al (2004). “Leuprorelin: Subcutaneous Depot Formulation (ELIGARD) for Advanced Prostate Cancer,” Am J. Cancer, 3(3):197-201. |
| FDA Document K982865 (1998). Atrix Laboratories, Inc. 13 pages. |
| FDA Document K994137 (2000). Atrix Laboratories, Inc. 9 pages. |
| Frank, K.R. et al (1994). “Controlled Release of Bioactive Growth Factors from a Biodegradable Delivery System,” PHREEB, 11(10):S88, Abstract No. 2070. |
| Frost, J.J., Wagner, H.N. Jr., Dannals, R.F., Ravert, H.T., Links, J.M., Wilson, A.A., Burns, H.D., Wong, D.F., McPherson, R.W., Rosenbaum, A.E., Kuhar, M.J. & Snyder, S.H. (1985). Imaging opiate receptors in the human brain by positron tomography. J Comp Assist Tomogr, 9, 231-236. |
| Gerentes, P. et al. (2002). “Study of a chitin-based gel as injectable material in periodontal surgery,” Biomaterials 23(5):1295-1302. |
| Graves, R.A. et al. (Aug. 3, 2007). “In vitro dissolution method for evaluation of buprenorphine in situ gel formulation: a technical,” AAPS PharmSciTech 8(3): Article 62, E1-E4. |
| Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, Schuster CR, Zubieta JK (2003) Neuropsychopharmacology 28: 2000-2009. |
| Greenwald MK, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn MR, Koeppe RA, Zubieta JK (2007) Buprenorphine duration of action: Mu-opioid receptor availability, pharmacokinetic and behavioral indices. Biological Psychiatry 61: 101-110. |
| Griffeth, R.J. et al. (2002). “Is Lucteal Production of PGF2α Required for Luteolysis?” Biology of Reproduction 66(Supplement 1), Abstract 465, 2 pages. |
| Hempel, G. et al. (May 1, 2007). “Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan,” J Clin Oncol 25(13)1772-1778. |
| Jain, R.A. (Dec. 2000). “The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices,” Biomaterials 21(23):2475-2490. |
| Jarr, E.M. et al. (Jul. 1999). “Sustained Release of Lidocaine from an Injectable Implant System for Treatmenr of Post-Operative,” Proceedings Int'l Symp Control Rel Bioact Materials Abstract #5423, 4 pages. |
| Johnson, O.L. et al. (Jun. 1997). “The stabilization and encapsulation of human growth hormone into biodegradable microspheres,” Pharm res 14(6):730-735. |
| Kaul, S. et al. (Feb. 2000). “Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB,” J Am Coll Cardiol 35(2):493-501. |
| Kissel, T. (Jan. 2002). “ABA-triblock copolymers from biodegradable polyester A-blocks and hydrophilic poly(ethylene oxide) B-blocks as a candidate for in situ forming hydrogel delivery systems for proteins,” Adv Drug Deily Rev 54(1):99-134. |
| Kranz, H. et al. (Jan. 5, 2001). “Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems,” Int J Pharm 212(1):11-18. |
| Lee, K.P. et al. (Aug. 1987). “Toxicity of N-methyl-2-pyrrolidone (NMP): teratogenic, subchronic, and two-year inhalation studies,” Fundam Appl Toxicol 9(2):222-235. |
| Lester PA, Traynor JR. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes. Brain Res. 2006;1073-1074:290-296. |
| Lewis JW., Buprenorphine. Drug Alcohol Depend. 1985; 14:363-372. |
| Li, M. et al. (Nov. 2003). “A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing,” Bone Miner Res 18(11):2033-2042. |
| Liao, C-L. et al. (2008). “In vitro skin permeation of buprenorphine transdermal patch,” Journal of Food and Drug Analysis 16(6):8-15. |
| Lindhardt et al, “Intranasal Absorption of Buprenorphine—in vivo biovavailability study in sheep.” Int. J. Pharm., 205(1-2):159-163 (2000). |
| Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch. Gen. Psychiatry. 1996; 53:401-407. |
| Ling W, Charuvastra C, Collins JF, Batki S, Brown LS, Jr, Kintaudi P, Wesson Dr, McNicholas L, Tusel DJ, Malkerneker U, Renner JA, Jr, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998; 93:475-486. |
| Lutfy K, Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr. Neuropharmacol. 2004; 2:395-402. |
| Lynch, G.S. et al. (Nov. 204). “Emerging drugs for sarcopenia: age-related muscle wasting,” Expert Opin Emerg Drugs 9(2);345-361. |
| Makadia, H.K. et al. (Sep. 1, 2011, e-published Aug. 26, 2011). “Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier,” Polymers 3(3):1377-1397. |
| Malik, K. et al. (2010). “Atrigel: A Potential Parenteral Controlled Drug Delivery System,” Der Pharmacia Sinica 1(1):74-81. |
| Matschke, C. et al. (Dec. 2007). “Sustained-release injectables formed in situ and their potential use for veterinary products,” J Control Release 85(1-3):1-15. |
| Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Rogues BP, Kieffer BL. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996; 383:819-823. |
| McLeod, D.G. et al. (Feb. 2003). “Hormonal therapy: historical perspective to future directions,” Urology 61(2 Suppl 1):3-7. |
| Mealy (2004). “Treatment of Metabolic Disorders by Condition,” Annual Update 2003/2004—Drugs of the Future 29(8):843-872. |
| Medicott, N.J. et al. (Jun. 23, 2004). “Sustained release veterinary parenteral products,” Adv Drug Deliv Rev 56(10):1345-1365. |
| Miller, R.A. et al. (Sep. 1977). “Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios,” Biomed Mater Res 11(5):711-719. |
| Mottu, F. et al. (Apr. 2000). “In vitro assessment of new embolic liquids prepared from preformed polymers and water-miscible solvents for aneurysm treatment,” Biomaterials 21(8):803-811. |
| Packhaeuser, C.B. et al. (Sep. 2004). “In situ forming parenteral drug delivery systems: an overview,” Eur J Pharm Biopharm 58(2):445-455. |
| Panaccione, C. et al. (1997). “Use of a Trinomial Distribution Probability Model in Development of a Tier-Testing Scheme for Content Uniformity Testing,” Drug Information Journal 31:903-909. |
| Paralkar, V.M. et al. (May 27, 2003, e-published May 14, 2003). “An EP2 receptor-selective prostaglandin E2 agonist induces bone healing,” PNAS USA 100(11):6736-6740. |
| Parent, M. et al. (Nov. 28, 2013, e-published Sep. 1, 2013). “PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release,” J Control Release 172(1):292-304. |
| Patel, R.B. et al. (Nov. 1, 2010, e-published Aug. 20, 2010). “Effect of injection site on in situ implant formation and drug release in vivo,” J Control Release 147(3):350-358. |
| Pechenov, S. et al. (Apr. 16, 2004). “Injectable controlled release formulations incorporating protein crystals,” J Control Release 96(1):149-158. |
| Perez-Merreno, R. (Nov. 2002). “A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer,” Clinical Therapuetics 24(11):1902-1914. |
| Perez-Marrero, R. et al. (Feb. 2004). “A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer,” Expert Opin Pharmacother 5(2):447-457. |
| Radomsky, M.L. et al. (1993). “The Controlled Release of Ganirelix from the Atrigel™ Injectable Implant System,” Proceed Intern Symp Control Rel Bioact Mater 20:458-459. |
| Rathbone, M.J. et al. (Aug. 1, 2002). “Modified release drug delivery in veterinary medicine,” Drug Discov Today 7(15):823-829. |
| Ravivarapu, H.B. et al. (Feb. 28, 2000). “Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant,” AAPS PharmSciTech 1(1):E1. |
| Ravivarapu, H.B. et al. (Jun. 2000). “Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate,” J Pharm Sci 89(6):732-741. |
| Ravivarapu, H.B. et al. (Jan. 25, 2000). “Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide,” Int J Pharm 194(2):181-191. |
| Schoenhammer, K. et al. (Apr. 17, 2009, e-published Dec. 24, 2008). “Injectable in situ forming depot systems: PEG-DAE as novel solvent for improved PLGA storage stability,” Int J. Pharm 371(1-2):33-39. |
| Schoenhammer, K. et al. (Dec. 2009, e-published Oct. 1, 2009). “Poly(ethyleneglycol) 500 dimethylether as novel solvent for injectable in situ forming depots,” Pharm Res 26(12):2568-2577. |
| Schulman, C.C. (2005). “LHRH Agonists in Prostate Cancer Optimising Testosterone Control with Eligard®,” European Urology Supplements 4:1-3. |
| Schwach-Abdellaoui, K. et al. (Jul. 2000). “Local delivery of antimicrobial agents for the treatment of periodontal diseases,” Eur J Pharm Biopharm 50(1):83-99. |
| Sherman, J.M. et al. (1994). “Localized Delivery of Bupivacaine HCL from Astrigel™ Formulations for the Management of Postoperative Pain,” Pharmaceutical Research 11(10), PDD7574, 2 pages. |
| Sigmon et al, “An injection depot formulation of buprenorphine: extended biodelivery and effects,” Addiction, 101:420-432 (2006). |
| Sinha, V.R. et al. (Jun. 18, 2004). “Poly-epsilon-caprolactone microspheres and nanospheres: an overview,” Int J. Pharm 278(1):1-23. |
| Smith, R.W. et al. (2004). “A Study of Water Diffusion, in Both Radial and Axial Directions, into Biodegradable Monolithic Depots Using Ion Beam Analysis,” Polymer 45:4893-4908. |
| Sobel et al, “Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification,” Drug and Alcohol Dependence, 73:11-22 (2004). |
| Southard, G.L. et al. (Feb. 1998). “Subgingival controlled release of antimicrobial agents in the treatment of periodontal disease,” Int J Antimicrob Agents 9(4):239-253. |
| Southard, G.L. et al. (Sep. 1998). “The drug delivery and biomaterial attributes of the ATRIGEL® technology in the treatment of periodontal disease,” Expert Opin lnvestig Drugs 7(9):1483-1491. |
| Sundaram, S. et al. (2004). “Peptides: Nasal and Pulmonary Delivery of Deslorelin, a Peptide Drug,” American Pharmaceutical Review 130-139. |
| Swanson, B.N. (Jan.-Jun. 1985). “Medical use of dimethyl sulfoxide (DMSO),” Rev Clin Basic Pharm 5(1-2):1-33. |
| Tipton, A.J. et al. (Oct. 1991). “A Biodegradable, Injectable Delivery System for NonSteroidal Anti-Flammatory Drugs,” Pharmaceutical Research 8(10), PDD 7279, 2 pages. |
| Titeler, M., Lyon, R.A., Kuhar, M.J., Frost, J.J., Dannals, R.F., Leonhardt, S., Bullock, A., Rydelek, L.T., Price, D.L. & Struble, R.G. (1989). Mu opiate receptors are selectively labeled by [3H]-carfentanil in human and rat brain. Eur J Pharmacol, 167, 221-228. |
| Tserki, V. et al. (Feb. 2006). “Biodegradable aliphatic polyesters. Part II. Synthesis and characterization of chain extended poly(butylene succinate-co-butylene adipate),” Polymer Degradation and Stability 91(2):377-384. |
| Tunn, U.W. (Jul. 29, 2011). “A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients,” BMC Urology 11:15. |
| Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 2010; 30: 155-166. |
| Winzenburg, G. et al. (Jun. 23, 2004). “Biodegradable polymers and their potential use in parenteral veterinary drug delivery systems,” Adv Drug Deliv Rev 56(10):1453-1466. |
| Wolff, E.D. et al. (1994). “Use of Bio-Beads SM-4 Adsorbent for Bioburden Testing of Atrigel™ Biodegradable Delivery System Containing 10% Doxycycline,” ASM Las Vegas 1994, Abstracts, 3 pages. |
| World Health Organization (2001). N-Methyl-2-Pyrrolidone, Concise International Chemical Assessment Document 35, 39 pages. |
| Xia, Y. et al. (Jul. 18, 2002). “Uniform biodegradable microparticle systems for controlled release,” J Control Release 82(1):137-147. |
| Zhu, G. et al. (2000). “Stabilization of proteins encapsulated in cylindrical poly(lactide-co-glycolide) implants: mechanism of stabilization by basic additives,” Pharm Res 17(3):351-357. |
| International Preliminary report on Patentability dated Jun. 29, 2016 for PCT Application No. PCT/GB2015/050676, filed Mar. 9, 2015, 18 pages. |
| International Search Report dated Jun. 11, 2015 for PCT Application No. PCT/GB2015/050676, filed Mar. 9, 2015, 6 pages. |
| Written Opinion dated Jun. 11, 2015 for PCT Application No. PCT/GB2015/050676, filed Mar. 9, 2015, 6 pages. |
| International Search Report and Written Opinion dated May 10, 2013 for priority application PCT/GB2011/051058. |
| International Preliminary Report on Patentability dated Dec. 20, 2012 for priority application PCT/GB2011/051058. |
| Search Report dated Oct. 6, 2010 for priority application GB1009546.1. |
| Ahmed, T.A. et al. (Oct. 2012, e-published Jun. 29, 2012). “Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol,” J Pharm Sci 101(10):3753-3762. |
| Ahmed, T.A. et al. (Jun. 2015, e-published Mar. 20, 2014). “Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability,” AAPS PharmSciTech 15(3):772-780. |
| Babu, R.J. et al. (May-Jun. 2005). “Effect of penetration enhancers on the transdermal delivery of bupranolol through rat skin,” Drug Deliv 12(3):165-169. |
| Buggins, T.R. et al. (Dec. 22, 2007). “The effects of pharmaceutical excipients on drug disposition,” Adv Drug Deliv Rev 59(15):1482-1503. |
| Cheng, Y. et al. (Dec. 2013, e-published Oct. 1, 2013). “Thermosensitive hydrogels based on polypeptides for localized and sustained delivery of anticancer drugs,” Biomaterials 34(38):10338-10347. |
| Dewan, I. et al. (2011). “Study of Release Kinetics of Dexamethasone from Biodegradable PLA In-Situ Implants,” International Journal of Pharmaceutical Science and Research 2(11):3039-3045. |
| Furuishi, T. et al. (Jul. 2007). “Effect of permeation enhancers on the in vitro percutaneous absorption of pentazocine,” Biol Pharm Bull 30(7):1350-1353. |
| Gou, M. et al. (Apr. 2010). “Polymeric matrix for drug delivery: honokiol-loaded PCL-PEG-PCL nanoparticles in PEG-PCL-PEG thermosensitive hydrogel,” J Biomed Mater Res A 93(1):219-226. |
| Ibrahim, H.M. et al. (Jan. 2014, e-published Jan. 9, 2013). “Development of meloxicam in situ implant formulation by quality by design principle,” Drug Dev Ind Pharm 40(1):66-73. |
| Jaiswal, J. et al. (Mar. 1, 1999). “Transdermal delivery of naloxone: ex vivo permeation studies,” Int J Pharm 179(1):129-134. |
| Kan, P. et al. (Jul. 21, 2005). “Thermogelling Emulsions for Vascular Embolization and Sustained Release Drugs,” Journal of Biomedical Materials Research 75B(1):185-192. |
| Karatas, A. et al. (2006). “Studies of Release of Ketorolac Tromethamin and Indomethacin from Opthalmic Hydrogel Inserts,” Ankara Ecz Fak Derg 35(4)255-268. |
| Kelava, T. et al. (2011). “Biological Actions of Drug Solvents,” Periodicum Biologorum 113(3):311-320. |
| Lin, X. et al. (2012). “A novel risperidone-loaded SAIB-PLGA mixture matrix depot with a reduced burst release: effects of solvents and PLGA on drug release behaviors in vitro/in vivo,” J Mater Sci Mater Med 23(2):443-455. |
| Madhu, M. et al. (Nov.-Dec. 2009). “Biodegradeable Injectable Implant Systems for Sustained DeliveryUsing Poly (Lactide-Co-Glycolide) Copolymers,” International Journal of Pharmacy and Pharmaceutical Sciences Vo1., Suppl 1, 103-107. |
| Mendelson, J.E. et al (Apr. 2011, e-published Dec. 8, 2010). “Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial,” Psychopharmacology 214(4):933-939. |
| Mownika, G. et al. (2012). “Formulation and Evaluation of Simvastatin Injectable in situ Implants,” American Journal of Drug Discovery and Development 2(2):87-100. |
| Nahata, T. et al. (Mar.-Apr. 2009). “Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design,” PDA J Pharm Sci Technol 63(2):113-122. |
| Olby, N. (Sep. 2010). “The pathogenesis and treatment of acute spinal cord injuries in dogs,” Vet Clin North Am Small Anim Pract 40(5):791-807. |
| Omidfar, K. et al. (2002). “Stabilization of Penicillinase-Hapten Conjugate for Enzyme Immunoassay,” Journal of Immunoassay & Immunochemistry 23(3):385-398. |
| Plourde, F. et al. (Nov. 28, 2005, e-published Sep. 21, 2005). “First report on the efficacy of l-alanine-based in situ-forming implants for the long-term parenteral delivery of drugs,” J Control Release 108(2-3):433-441. |
| Pluta, J. et al. (Dec. 20, 2006). “In vitro studies of the properties of thermosensitive systems prepared on Pluronic F-127 as vehicles for methotrexate for delivery to solid tumours,” Polymers in Medicine 36(3):37-52. |
| Rackur, H. et al. (2001). “In-Situ Forming Implants of PLGA/Leuprolide Acetate Solutions in NMP and Their in Vitro/in Vivo Release Characteristics,” 28th International Symposium on Controlled Release of Bioactive Materials and Fourth Consumer Products Conference, 2001 Proceedings, Abstract 6137, pp. 884-885. |
| Rafienia, M. et al. (Jul. 2007). “In Vitro Evaluation of Drug Solubility and Gamma Irradiation on the Release of Betamethasone under Simulated in Vivo Conditions,” Journal of Bioactive and Compatible Polymers 22:443-459. |
| Reilley,K.J. et al. (Nov. 17, 2010). “Prevention of Cocaine-Conditioned Place Preference with Salvinorin a Prepared with Optimal Vehicle Conditions,” 40th Annual Meeting Neuroscience 2010, Presentation Abstract, 2 pages. |
| Toot, J.D. et al. International Journal of Toxicology 32(1):66. |
| Wang, L. et al. (May 10, 2012, e-published Feb. 23, 2012). “Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism,” Int J Pharm 427(2):284-292. |
| Wischke, C. et al. (Oct. 2010, e-published Jul. 29, 2010). “Development of PLGA-based injectable delivery systems for hydrophobic fenretinide,” Pharm Res 27(10:2063-2074. |
| Wu, Z. et al. (Oct. 2014, e-published Jul. 1, 2014). “Thermosensitive hydrogel used in dual drug delivery system with paclitaxel-loaded micelles for in situ treatment of lung cancer,” Colloids Surf B Biointerfaces 122:90-98. |
| Yaksh, T.L. et al. (1991). “The utility of 2-hydroxpropyl-beta-cyclodextrin as a vehicle for the intracerebral and intrathecal administration of drugs,” Life Sci 48(7):623-633. |
| Yang, Y. et al. (May 2012, e-published Mar. 15, 2012). “Improved initial burst of estradiol organogel as long-term in situ drug delivery implant: formulation, in vitro and in vivo characterization,” Drug Dev Ind Pharm 38(5):550-556. |
| Yehia, S.A. et al. (Jun. 2012, e-published Nov. 18, 2011). “A novel injectable in situ forming poly-DL-lactide and DL-lactide/glycolide implant containing lipospheres for controlled drug delivery,” J Liposome Res 22(2):128-138. |
| Chemical Solution, definition of Chemical Solution by Medical Dictionary, located at <https://medical-dictionary. thefreedictionary.com/Chemical+solution> last visited Dec. 29, 2017, 10 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20160184296 A1 | Jun 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13703015 | US | |
| Child | 15060184 | US |
